Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study

NCT06494241 · tracked via the Priya Life Science China tracker

Sponsor

AstraZeneca

Phase

Observational

Started

2024-11-22

Last updated

2026-06-02

Condition(s) studied

Carcinoma, Non-Small-Cell LungLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesCarcinoma, BronchogenicBronchial Neoplasms

Study summary

To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP; To evaluate the treatment pattern in metastatic NSCLC patients after QIP.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Age ≥18 years, at the time of signing the informed consent. * ECOG performance status 0-2. * Newly pathologic diagnosed metastatic NSCLC (clinical stage IV) or recurrent metastatic NSCLC. Exclusion Criteria: * Be participating in other intervention clinical trials. * Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. * Previous enrolment in the other QIP study.

Primary outcome measure(s)

To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP — Approximately 1 month after last patient in
Molecular testing-rate for the first-line treatment: Defined as the number of participants received molecular testing for the first-line treatment divided by total participants.
To evaluate the treatment pattern in metastatic NSCLC patients after QIP — Approximately 1 month after last patient in
TKIs first-line treatment rate: Defined as TKIs first-line treatment rate in AGA positive participants.

Trial sites (46)

Facility	City	Region
Research Site	Anning	China
Research Site	Anqing	China
Research Site	Changzhi	China
Research Site	Daqing	China
Research Site	Dazhou	China
Research Site	Dazhu	China
Research Site	Dingzhou	China
Research Site	Ganzhou	China
Research Site	Guangzhou	China
Research Site	Guang’an	China
Research Site	Hanzhong	China
Research Site	Hebi	China
Research Site	Hengyang	China
Research Site	Huaibei	China
Research Site	Jining	China
Research Site	Jinzhou	China
Research Site	Liyang	China
Research Site	Lu'an	China
Research Site	Meihekou	China
Research Site	Nanchong	China
Research Site	Nanyang	China
Research Site	Ningde	China
Research Site	Ningxiang	China
Research Site	Panjin	China
Research Site	Pingxiang	China
Research Site	Quanzhou	China
Research Site	Shengzhou	China
Research Site	Suzhou	China
Research Site	Taizhou	China
Research Site	Tancheng	China
Research Site	Tongling	China
Research Site	Wafangdian	China
Research Site	Weifang	China
Research Site	Wuzhou	China
Research Site	Xiangtan	China
Research Site	Xianning	China
Research Site	Xiantao	China
Research Site	Xixian	China
Research Site	Xuzhou	China
Research Site	Yangjiang	China

+ 6 more sites — see the full list on the official registry below.

More AstraZeneca trials in China

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight Active, not recruiting

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) Active, not recruiting

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) Active, not recruiting

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs Recruiting

The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management Recruiting

Other trials for the same condition

Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation Recruiting

Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Active, not recruiting

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) Active, not recruiting

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation Active, not recruiting

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06494241 on ClinicalTrials.gov ↗ ← All trials in China